Anastasios Tsolakidis
Ass. Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (17)
Year:
2026
Year:
2026
Year:
2026
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Objectives Patients with RA were at increased risk for COVID-19-associated hospitalization and death during the first year of the pandemic in Greece. We aimed to examine their outcomes after the SARS-Cov-2 Omicron, a more contagious but with milder clinical impacts variant, prevailed. Methods A retrospective, nationwide study was conducted between 1 January 2022 and 30 June 2022 in all RA patients under treatment and matched (1:5) on age, sex and region of domicile random general population comparators. Confirmed SARS-CoV-2 infections, hospitalizations and deaths, anti-rheumatic medications, prior COVID-19, vaccinations and anti-viral medications were recorded. Results Among 34 182 RA patients, infections (n = 5569, 16.29%), hospitalizations (n = 489, 1.43%) and deaths (n = 106, 0.31%) were more frequent than among comparators. Incidence rates per 1000 person/years of infection [IRR (95% CI):1.19 (1.16, 1.23)], hospitalization [IRR (95% CI):2.0 (1.82, 2.24)], and death [IRR (95% CI):1.81 (1.44, 2.27)] were increased in RA despite better vaccination coverage (89% vs 84%) and more frequent use of anti-viral medications (2.37% vs 1.08). Logistic regression analysis after correcting for age, sex, vaccinations, prior COVID-19, and anti-viral medications in SARS-CoV-2 infected RA patients and comparators revealed increased risk of hospitalization (OR: 2.02, 95% CI: 1.79, 2.27) and death [OR: 1.73, (95% CI: 1.36, 2.20)] in RA. Among infected RA patients, rituximab treatment conferred increased risks for hospitalization [OR: 6.12, (95% CI: 2.89, 12.92)] and death [OR: 12.06 (95% CI: 3.90, 37.31)], while JAK inhibitors increased only hospitalization risk [OR: 2.18 (95% CI: 1.56, 3.06)]. Conclusion RA remains a risk factor for hospitalization and death in an era of a relatively low COVID-19 fatality rate, pointing to the need of perseverance in vaccination programs and wider use of anti-viral medications.
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (11)
Dimitris Kouis
Assistant Professor
University of West Attica
PANAGIOTA MITROU
Head
Ministry of Health
Elizabeth Lazaridou
Professor of Dermatology-Venereology
Aristotle University of Thessaloniki
Dimitrios Paraskevis
Professor
Ethniko kai Kapodistriako Panepistemio Athenon Iatrike Schole
Dimitra Ioanna Lampropoulou
Assistant Professor of Clinical Pharmacology
UNIVERSITY OF PELOPONNESE
Nikolaos Thomaidis
PROFESSOR
National and Kapodistrian University of Athens
Petros P Sfikakis
National and Kapodistrian University of Athens
Christos Skourlas
University of West Attica
Athina Markou
National and Kapodistrian University of Athens
George E Fragoulis
Rheumatologist
National and Kapodistrian University of Athens
Nikitas Karanikolas
Professor
University of West Attica
Make your next move.
Prepare your application
Review drafts before you send them.